Suven gets granted 20th patent from Europe and 8th from Macau patent

Suven Life Sciences Ltd (SUVEN) has got the grant of one product patent from Europe and one product patent from Macau corresponding to the New Chemical Entities (NCEs) for the treatment of disorders associated with Neurodegenerative diseases and these Patents are valid through 2030 and 2029.

The granted claims of the patents include the class of selective alpha-4-beta-2 compounds discovered by Suven and are being developed as therapeutic agents for major depressive disorder (MDD).

With these new patents, Suven has a total of twenty granted patents from Europe and eight granted patents from Macau.

Products out of these inventions may be out-licensed at various phases of clinical development like at Phase-I or Phase-II.

“We are very pleased by the grant of these patents to Suven for our pipeline of molecules in CNS arena that are being developed for Major Depressive Disorder (MDD) with high unmet medical need with huge market potential globally” says Venkat Jasti, CEO of Suven.